Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, UBS Group Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by investment analysts at UBS Group from $145.00 to $155.00 in a research report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price target indicates a potential upside of 9.95% from the stock’s previous close.

Several other equities analysts have also recently issued reports on GILD. Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. Morgan Stanley decreased their price objective on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Scotiabank assumed coverage on Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price for the company. Wolfe Research reaffirmed an “outperform” rating and set a $150.00 target price on shares of Gilead Sciences in a report on Monday, December 15th. Finally, Wells Fargo & Company increased their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $135.36.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $140.97 on Monday. The company’s 50 day moving average price is $124.53 and its two-hundred day moving average price is $119.10. The firm has a market capitalization of $174.90 billion, a P/E ratio of 21.86, a P/E/G ratio of 0.72 and a beta of 0.33. Gilead Sciences has a fifty-two week low of $93.37 and a fifty-two week high of $141.71. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 247,397 shares of company stock valued at $31,986,612 over the last ninety days. Insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. GoalVest Advisory LLC increased its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $26,000. Financial Consulate Inc. increased its stake in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares in the last quarter. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences during the second quarter worth $27,000. Finally, BOCHK Asset Management Ltd bought a new position in shares of Gilead Sciences in the fourth quarter valued at $31,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple major banks raised price targets and kept bullish ratings, increasing investor conviction that upside remains (Citigroup to $156, UBS to $155, BMO to $150, Truist to $145). Analysts cited in these notes are maintaining buy/outperform views, which supports demand for GILD. Citigroup price‑target note UBS/Truist coverage BMO note
• Positive Sentiment: Press reports note GILD reached a new 1‑year high on the analyst upgrade momentum — a technical trigger that can attract momentum buyers and ETFs. AmericanBankingNews article
• Neutral Sentiment: Company fundamentals and guidance remain supportive: Gilead’s most recent quarter beat EPS and revenue expectations and management set FY2025 EPS guidance (8.05–8.25), which underpins analyst optimism but is not new today. (See analyst consensus and company metrics for context.) MarketBeat company summary
• Negative Sentiment: GILD’s CEO, Daniel Patrick O’Day, sold 115,640 shares (avg $135) in a disclosed transaction — a large insider sale that may prompt concern or profit‑taking among some investors despite his remaining sizeable stake. The SEC filing and trade detail are public. SEC Form 4 (insider sale) InsiderTrades report

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.